Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XR 311

Drug Profile

XR 311

Alternative Names: HN 66000; KSB 311M; KSB 311N; KSB 311P; KSB 311R; PEP04; Project KSB311R; SOT-107; TF CRM 107; Transferrin-CRM 107; TransMID; TransMID 107M; TransMID 107N; TransMID 107P; TransMID 107R

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare; National Institutes of Health (USA)
  • Developer Nycomed; Sosei; Xenova Group
  • Class Antineoplastics; Drug conjugates; Immunotoxins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - CNS cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS cancer; Glioblastoma; Glioma

Most Recent Events

  • 19 Apr 2005 Xenova has licensed XR 311 to PharmaEngine in the Republic of China and in the Republic of South Korea
  • 14 Feb 2005 XR 311 has received orphan drug status for glioma in Japan
  • 07 Jul 2004 Phase-III clinical trials in Glioblastoma in European Union (Intratumoural)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top